Efficacy and safety of Yukmijihwang-tang added to insulin-metformin therapy in patients with type 2 diabetes -a pilot study

Daegu Catholic Univercity Medical Center0 个研究点目标入组 14 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•Patients are eligible to be included in the study only if they meet all of the following criteria;
•? Subject who is more than18 years of age and younger than 80 years of age has been diagnosed with type 2 diabetes mellitus.
•? Subject who has been treated with metformin and insulin for at least 3 months has a Hb A1c value more than 7.5%, and should be required more intense medications, based on the investigator's judgement.
•? Subject agrees to participate in this study and writes Informed consent.

•Paitent will be excluded from the study if they meet any of the following criteria;
•? Subject has developed weight loss due to poorly controlled glucose for at least 3 months.
•? Subject has taking the any drugs including weight loss medication which have the potential confounding effect in the study.
•? Subject has a history of imparied thyroid function.(Exceptionally, if the patient is left with the normal functioning thyroid for at least 6 months, he/she can be included)
•? Subject is participating in another clinical study.
•? Subject has a history of an active malignancy or serious conditions such as hepatic or renal disease.
•? Subject is the female of childbearing potential who are pregnant,breast-feeding, or not using adequate contraceptive methods
•? Subject has episodes of nause, vomiting, or acute gastrointestinal symptom within the 2 weeks before

发起方

Daegu Catholic Univercity Medical Center